EPP News Bureau – Mumbai
Labs Ltd, the Rs 250 crore Bangalore-based nutraceuticals
and herbal extracts producer which has bagged three patents
for tetrahydrocurcuminoids (THC), Coleus oil and ZeaLutien,
is planning to enter the formulations segment in the country.
The company’s CMD Dr Muhammed Majeed said here today
that they have asked Ernst and Young to chart out the consolidation
of group companies and expansion of the company either through
the IPO route or private investment.
Dr Majeed said he expects around Rs 200 crores to be pumped
into the company to expand its marketing and research network.
Sami is also planning to enter the nutraceutical and ethical
pharmaceutical formulations business in India in future.
Sami is targeting a business of Rs 100 crores by 2006.
The company is working on four natural drug molecules which
have cleared the toxicity screening, he said.
The company’s three new active ingredients - tetrahydrocurcuminoids
(THC), Coleus oil and ZeaLutien have been approved for the
dermatology, infective and geriatric ophthalmology markets.
THCs are the while curcuminoids converted from the yellow
active ingredient from turmeric. The component has significant
anti-oxidant application and UV protection. The process
of conversion from yellow to white improves bioavailability
and eliminates the staining properties of curcuminoids.
Lutien and its derivatives are used in ophthalmic drugs
to treat age-related macular degeneration (AMD). The process
of stabilisation of lutein improves longevity of the drug
and its prevention of AMD oil extracted from Coeus Forskohli
has strong anti-microbial properties especially in fighting
gram positive infections and dental microbial activity.
He hopes to capture five per cent of the total global market
in the netx three years with these discoveries.
A pioneer in the nutraceuticals industry, the company is
a leading exporter of standardised herbal extracts, fine
chemicals, specialty chemicals, cosmeceuticals, phytonutrients